LBL Biotechnology Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor (US 11,661,450) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Mar 8, 2027The maintenance fee for Methods for treating osteoporosis with anti-IL-20 receptor antibodies (US 9,127,066) comes due Mar 8, 2027. Unpaid by Sep 8, 2027, it lapses early.
- 2 fees due Jun 22 to 29, 2027 · next Jun 22
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,611,705 | ANTI-IL-20 Antibody and Its Use in Treating IL-20 Associated Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 8,012,478 | Use of ANTI-IL-20 Antibody for Treating Stroke In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 7,837,994 | Use of ANTI-IL-20 Antibody for Treating Osteoporosis In force · High confidence | In force | High confidence | |
| US 8,454,956 | Methods for Treating Rheumatoid Arthritis and Osteoporosis with ANTI-IL-20 Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 9,127,066 | Methods for treating osteoporosis with anti-IL-20 receptor antibodies In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence | |
| US 8,535,674 | Treating Breast Cancer and Inhibiting Cancer-Associated Bone loss with Anti-IL-20 Antibody In force · Medium confidence | In force | Medium confidence | |
| US 8,597,647 | Humanized ANTI-IL-20 Antibody and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,217,031 | Humanized Anti-IL-20 Antibody And Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,603,470 | Use of IL-20 Antagonists for Treating Liver Diseases In force · High confidence | In force | High confidence | |
| US 8,852,588 | Treating Allergic Airway Disorders Using ANTI-IL-20 Receptor Antibodies In force (reinstated) · High confidence | In force (reinstated) | High confidence |
Also on record, not counted in the 20: 3 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.